Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey

Psychopharmacology

Volumn 178, Issue 2-3, 2005, Pages 339-346

  Anderson, George M ^a   Barr, Christina S ^b   Lindell, Stephen ^b   Durham, Amy C ^b   Shifrovich, Ilya ^a   Higley, J Dee ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

5 Hydroxyindoleacetic acid; Cerebrospinal fluid; Cisternal; CSF; Rhesus monkey; Selective serotonin reuptake inhibitor; Serotonin; Sertraline; SSRI

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONIN BLOOD LEVEL; THROMBOCYTE;

ANIMALS; BRAIN; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MACACA MULATTA; MALE; REFERENCE VALUES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TRYPTOPHAN;

EID: 15044341427     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2011-7     Document Type: Article

References (57)

1. Anderson GM, Teff KL, Young SN (1987a) Serotonin in cisternal cerebrospinal fluid of the rat: measurement and use as an index of functionally active serotonin. Life Sci 40:2253-2260
2. Anderson GM, Feibel FC, Cohen DJ (1987b) Determination of serotonin in whole blood, PRP, PPP and plasma ultrafiltrate. Life Sci 40:1063-1070
3. Anderson GM, Mefford IN, Tolliver TJ, Riddle MA, Ocame DM, Leckman JF, Cohen DJ (1990) Serotonin in human lumbar cerebrospinal fluid: a reassessment. Life Sci 46:247-255
4. Anderson GM, Bennett AJ, Weld KP, Pushkas JG, Ocame DM, Higley JD (2002) Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology 161:95-99
5. Aronoff GR, Bergstrom RF, Poltratz ST, Sloan RS, Wolen RL, Lemberger L (1984) Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36:138-144
6. Barr CS, Newman TK, Shannon C, Parker C, Dvoskin RL, Becker ML, Schwandt M, Champoux M, Lesch KP, Goldman D, Suomi SJ, Higley JD (2004) Rearing condition and rh5-HTTLPR interact to influence limbic-hypothalamic-pituitary-adrenal axis response to stress in infant macaques. Biol Psychiatry 55:733-738
7. Bel N, Artigas F (1992) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 278:1064-1072
8. Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245
9. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19:10494-10501
10. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22:6766-6772
11. Bennett AJ, Lesch KP, Heils A, Long JC, Lorenz JG, Shoaf SE et al (2002) Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry 7:118-122
12. Black K, Shea C, Dursun S, Kutcher S (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261
13. Blier P, De Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
14. Brammer GL, Raleigh MJ, McGuire MT, Rubinstein EH (1987) Comparison of ketamine, physical restraint, halothane and pentobarbital: lack of influence on serotonergic measures in monkeys and rats. Neuropharmacology 26:1615-1621
15. Bunin MA, Wightman RM (1999) Paracrine neurotransmission in the CNS: involvement of 5-HT. Trends Neurosci 22:377-382
16. Carpenter L, Anderson GM, Siniscalchi JM, Chappell PB, Price LP (2003) Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28:339-347
17. Catterson ML, Preskorn SH (1996) Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 78:203-208
18. Clarke AS, Ebert MH, Schmidt DE, McKinney WT, Kraemer GW (1999) Biogenic amine activity in response to fluoxetine and desipramine in differentially reared rhesus monkeys. Biol Psychiatry 46:221-228
19. Collins JM, Dedrick RL (1983) Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 245:R303-R310
20. DeVane CL, Liston HL, Markowitz JS (2002) Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247-1266
21. Eccleston D, Ashcroft GW, Moir ATB, Parker-Rhodes A, Lutz W, Mahoney DP (1968) A comparison of 5-hydroxyindoles in various regions of dog brain and cerebrospinal fluid. J Neurochem 15:947-957
22. Epperson N, Czarkowski KA, Ward-O'Brien D, Weiss E, Gueorguieva R, Jatlow P, Anderson GM (2001) Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry. 158:1631-1637
23. Frazer A, Benmansour S (2002) Delayed pharmacological effects of antidepressants. Mol Psychiatry 7:S23-S28
24. Gur E, Dremencov E, Lerer B, Newman ME (1999a) Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol 372:17-24
25. Gur E, Lerer B, Newman ME (1999b) Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther 288:81-87
26. Hammarlund-Udenaes M (2000) The use of microdialysis in CNS drug delivery studies pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 45:283-294
27. Higley JD, Suomi SJ, Linnoila M (1991) Development, rearing history, and sex differences in CSF monoamine metabolites. Psychopharmacology 103:551-556
28. Higley JD, Suomi SJ, Linnoila M (1992) A longitudinal study of CSF monoamine metabolite and plasma cortisol concentrations in young rhesus monkeys: effects of early experience, age, sex and stress on continuity of interindividual differences. Biol Psychiatry 32:127-145
29. Invernizzi R, Bramante M, Samanin R (1996) Role of 5-HT(1A) receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav 54:143-147
30. Katz MM, Koslow SH, Frazer A (1997) Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 4:257-267
31. Kihara T, Ikeda M (1995) Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272:177-183
32. Kornhuber J, Retz W, Rieder P (1995) Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuropletic and antidepressant drugs? J Neural Transm 46:315-323
33. Landen M, Eriksson E (2003) How does premenstrual dysphoric disorder relate to depression and anxiety disorders? Depress Anxiety 17:122-129
34. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L (1989) Fluoxetine treatment of depression. Acta Scand Psychiatr 79:589-596
35. Matsumoto M, Togashi H, Yoshioka M, Morii K, Hirokami M, Tochihara M, Ikeda T, Saito Y, Saito H (1991) Significant correlation between cerebrospinal fluid and brain levels of norepinephrine, serotonin, and acetylcholine in anesthetized rats. Life Sci 48:823-829
36. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 16:826-835
37. Mulder EJ, Anderson GM, Kema IP, Minderaa RB (2002) Reactivity of whole blood serotonin. Biol Psychiatry 51:266-268
38. Nutt DJ (2003) Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 17:355-364
39. Perry KW, Fuller RW (1992) Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50:1683-1690
40. Renshaw P, Guimaraes A, Fava M, Rosenbaum J, Pearlman J et al (1992) Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 149:1592-1594
41. Riddle MA, Anderson GM, McIntosh S, Harcherik DF, Shaywitz BA, Cohen DJ (1986) Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: age and sex effects and individual variability. Biol Psychiatry 21:69-83
42. Rollema H, Clarke T, Sprouse JS, Schulz DW (1996) Combined administration of a 5-hydroxytryptamine [5-HT(1D)] antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in Guinea pig hypothalamus in vivo. J Neurochem 67:2204-2207
43. Ronfeld RA, Tremaine LM, Wilner KD (1997) Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32(Suppl 1):22-30
44. Rosen R, Menza M, Lane R (1999) Effects of SSRIs on sexual dysfunction: critical review. J Clin Psychopharmacol 19:67-85
45. Rutter J, Gundlah C, Auerbach SB (1994) Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 171:183-186
46. Sarkissian CF, Wurtman RJ, Morse AN, Gleason R (1990) Effects of fluoxetine or D-fenfluramine on serotonin release from, and levels in, rat frontal cortex. Brain Res 529:294-301
47. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J (1997) Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel. J Clin Psychiatry 58(Suppl 7):5-10
48. Selim M, Bradberry CW (1996) Effect of ethanol on extracellular 5-HT and glutamate in the nucleus accumbens and prefrontal cortex: comparison between the Lewis and Fischer 344 rat strains. Brain Res 716:157-164
49. Sheline Y, Bardgett ME, Csernansky JG (1997) Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 17:11-14
50. Smith T, Kuczenski R, George-Friedman K, Malley JD, Foote SL (2000) In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 38:460-470
51. Sprouse J, Clarke T, Reynolds L, Heym J, Rollema H (1996) Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 14:225-231
52. Sprouse J, Braselton J, Reynolds L, Clarke T, Rollema H (2001) Activation of postsynaptic 5-HT(1A) receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies. Synapse 41:49-57
53. Steiner M, Pearlstein T (2000) Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 61(Suppl 12):17-21
54. Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN (2000) Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol 130:242-248
55. Wood JH (1980) Neurobiology of cerebrospinal fluid. Plenum, New York, pp 1-16
56. Yonkers K (1997) The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 58(Suppl 15):19-25
57. Zhou FC, Tao-Cheng J, Segu L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805:241-254